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ABSTRACT 
 
Ligand binding to the epidermal growth factor receptor (EGFR) on the cell surface elicits 
activation of the extracellular signal-regulated kinase (ERK) mitogen-activated protein 
kinase (MAPK) cascade. Signaling is presumably terminated by both internalization and 
ESCRT (endosomal sorting complex required for transport)-dependent sorting of the 
receptor into intralumenal vesicles of multivesicular endosomes. Here, we showed that 
depletion of ESCRTs had little effect on the overall architecture and amplitude of the EGF 
response, whereas the abundance of some transcripts involved in nuclear factor κB and 
cytokine signaling increased. However, interfering with receptor endocytosis or 
ubiquitination stimulated increases in the abundance of many EGF-induced transcripts, 
similar to that induced by EGFR overexpression. We also found that the complete EGF 
transcriptional program was set in motion within a relatively short time period following 
ligand binding to the receptor. We conclude that the transcriptional response is elicited 
primarily by receptor molecules at the cell surface or by internalized EGFR cycling back to 
the plasma membrane. 
  
INTRODUCTION 
 
Like other signaling receptors, the epidermal growth factor (EGF) receptor (EGFR) is 
endocytosed upon stimulation with ligand and transported to lysosomes for degradation, 
thereby protecting cells from excess activation (1). After internalization, ubiquitinated 
EGFR molecules are incorporated into intralumenal vesicles of multivesicular endosomes 
(2-4), uncoupling the cytoplasmic domain from its signaling effectors in the cytosol. 
Intralumenal vesicles with their receptor cargo are then transported to lysosomes and 
degraded (5, 6). Sorting into intralumenal vesicles is controlled by CBL-mediated 
ubiquitination of the receptor cytoplasmic domain (7, 8). Ubiquitin molecules bind the 
clathrin adaptor HRS (hepatocyte growth factor-regulated tyrosine kinase substrate), a 
subunit of ESCRT-0 (endosomal sorting complex required for transport), which in turn 
recruits ESCRT-I, -II and -III, leading to receptor incorporation into intralumenal vesicles. 
ESCRTs couple receptor sorting with the membrane deformation and fission process (7, 9) 
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during the formation of intralumenal vesicles containing the EGFR (10). Conversely, EGF 
itself regulates the pathway, because addition of EGF increases the number of 
multivesicular endosomes that form in an ESCRT-dependent manner (11, 12). 
Endocytic membrane traffic is also believed to orchestrate the signaling response (13-
20). Clathrin-mediated endocytosis of the EGFR was proposed to control specific signaling 
pathways (21), or to be a prerequisite for EGF-dependent biological responses through 
receptor recycling (22). By contrast, a clathrin-independent pathway may target the 
receptor for degradation (22-24) at least in some cell types (25). 
In contrast to other ligands, EGF remains receptor-bound in endosomes, whether EGFR 
is recycled (26) or is transported to lysosomes for degradation (1). Thus EGFR remains in 
principle signaling-competent, and endosomes indeed contain active EGFR and most 
components of the extracellular signal-regulated kinase (ERK) and mitogen-activated 
protein kinase (MAPK) (ERK/MAPK) cascade (13, 27). This may explain how some 
growth factors can elicit a complex, sometimes diverse, response through waves of 
compartmentalized signaling that are spatially and temporally regulated (14, 15, 17, 19, 
28). This notion is further supported by the findings that a MAPK scaffold complex 
consisting of p14, MP1 (MEK partner 1) (29) and p18 (30) is present on late endosomes 
and required for full activity of the MAPK cascade. It is however not clear whether EGFR 
is itself part of this endosomal signaling complex, nor is it clear how the pool of active 
endosomal receptor is regulated and the extent to which it contributes to the biological 
response. Here, we have investigated how membrane traffic and receptor sorting along the 
endocytic pathway regulate the EGF-mediated transcriptional response. 
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RESULTS  
 
Depletion of ESCRT subunits or VPS4A does not increase EGF signaling  
To study the acute signaling response triggered by EGF in live cells over time, we used a 
reporter HeLa cell line that stably expresses the activator domain of ELK1 (a transcription 
factor downstream of ERK) and contains a luciferase expression cassette (HLR-ELK1) 
(31). Luciferase activity was measured in a light-tight incubator equipped for light 
detection. Addition of EGF increased luciferase activity (Fig. 1A) in a manner that was 
sensitive to tyrphostin (AG1478), which inhibits the tyrosine kinase activity of EGFR (32). 
The signal was reduced by EGFR knockdown to ≈20% (above background) of the mock-
treated control (Fig. 1B), and could be increased to ≈250% by EGFR overexpression (Fig. 
1C), and to ≈400% by stimulation with the phorbol ester PMA (phorbol-12-myristate-13-
acetate) which activates ERK through protein kinase C (PKC) (33) (Fig. 1D). Finally, the 
EGF response was inhibited by double knockdown of MEK1 and MEK2 (MEK1/2) (Fig. 
1E) or with MEK1/2 inhibitor U0126 (Fig. 1F). The effects of tyrphostin on luciferase 
expression (Fig. 1A) were specific because the drug inhibited phosphorylation of EGFR, 
MEK1/2, and ERK1/2 in EGF-stimulated samples but not in PMA-treated cells (Fig. 1G). 
Verification of EGFR knockdown, EGFR overexpression and MEK1/2 double knockdown 
are shown in Fig. 1H-J. Altogether, these observations indicate that the assay was sensitive 
and robust, with a wide dynamic range, and that it faithfully reproduced the EGF response 
along the MAPK signaling cascade. 
 
Next, we investigated whether interfering with EGFR sorting into the multivesicular 
endosome and lysosome targeting affected the EGF signal. First, we depleted the ESCRT-0 
subunit HRS, which initiates the sequence of ESCRT-I, -II, and -III recruitment. Depletion 
of HRS inhibits intralumenal vesicle formation (34-37), leading to the formation of 
“empty” multivesicular endosomes. In such a situation, EGFR is not targeted to lysosomes 
and is retained at the limiting membrane of endosomes, leading to prolonged half-life and 
phosphorylation of EGFR and its downstream kinases (20). Consistent with these notions, 
knockdown of HRS inhibited sorting of EGFR into multivesicular endosomes that had been 
enlarged by overexpression of the Gln79→Leu (Q79L) constitutively active mutant of the 
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small GTPase RAB5, as expected (37-39) (Fig. 2A). However, HRS knockdown did not 
result in increased or sustained EGF signaling in our assay (Fig. 2B). Similarly, depletion 
of the ESCRT-I subunit TSG101 (tumor susceptibility gene 101), which interacts with HRS 
(35, 40) and is required for intralumenal vesicle formation (10, 36, 41, 42), did not affect 
luciferase activity (Fig. 2B). This lack of effect did not result from an exhaustion of the 
response or technical shortcomings, because the signal could be increased by receptor 
overexpression or PMA stimulation (Fig. 1C-D). Finally, we confirmed our analysis by 
showing that knockdown of HRS or TSG101 did not significantly affect the transcriptional 
induction of EGR1 and FOS mRNAs (Fig. 2C). Both are endogenous targets that are 
activated in the immediate early EGF response downstream of the ERK/MAPK cascade. 
Similarly, EGR1 and FOS induction was unaffected after knockdown of the ATPase 
VPS4A (vacuolar protein sorting 4A) (Fig. 2C), an essential ESCRT-associated protein that 
catalyzes disassembly of the ESCRT-III complex (7). 
 
After depletion of HRS or TSG101, EGFR degradation is reduced and phosphorylation 
of EGFR (34) and downstream kinases is prolonged (20), leading to the notion that 
signaling is sustained when ESCRT functions are blocked. We thus analyzed abundance of 
EGFR as well as phosphorylation state of EGFR and its downstream kinases over a time 
course that covered EGFR transcriptional response and degradation (43). As expected, 
EGFR abundance decreased after addition of EGF to mock-treated cells, with ≈25% 
remaining after 5 hours in the presence of cycloheximide (Fig. 2D; Fig. S1; Table S1). 
Knockdown of HRS or TSG101 (Fig. S2) delayed EGFR degradation to an extent similar to 
that previously observed by others (36, 44) and us (37), and concomitantly increased the 
phosphorylation state of EGFR and its downstream kinases, MEK1/2 and ERK1/2 (Fig. 
2D; Fig. S1; Table S1). Similarly, knockdown of VPS4A inhibited EGFR degradation and 
increased the phosphorylation state of the receptor, MEK1/2 and ERK1/2 (Fig. 2D; Fig. S1; 
Table S1). Depletion of each different ESCRT subunit affected phosphorylation of EGFR, 
MEK and ERK in a similar manner. Hence, interfering with the ESCRT pathway increases 
the activation state of the receptor and downstream kinases, but does not enhance the 
transcriptional induction of the luciferase reporter gene, or the expression of the 
endogenous target genes EGR1 and FOS.  
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The architecture of the EGF-dependent transcriptional response is not affected by 
depletion of ESCRT subunits or ESCRT-associated proteins  
The apparent discrepancy between the activation state of EGFR and MAPK and the 
signaling output at the level of transcription prompted us to investigate the EGF response in 
more detail. To this end, we analyzed the HeLa cell transcriptome at various time points 
after EGF stimulation. The addition of EGF resulted in greater than 1.8-fold changes in the 
abundance of more than 260 mRNAs above or below that in serum-starved cells (Fig. 3A-
B; Table S2). Normalization to mock-treated controls in the absence of EGF (lane m in Fig. 
3B at time 0 min) and grouping according to the peak (or minimum) of transcription 
showed that the EGF response was well orchestrated in time, consistent with previous 
observations (43). The expression of immediate early genes, encoding primarily 
transcription factors such as FOS and EGR1 (Fig. 3B and Fig. S3), was stimulated within 
30 min of EGF addition and then decreased at later time points. Factors encoded by these 
transcripts control subsequent steps of the response (43) and thus, cycloheximide was 
omitted to allow full deployment of the EGF response. At later time points, the 
transcription of a second and then a third wave of genes encoding for cellular effectors as 
well as additional feedback regulators was stimulated (Table S2 and Fig. S3) (43, 45). 
 
We next determined the extent to which the expression of EGF-regulated transcripts was 
altered after depletion of HRS, TSG101, VPS4A, or the ESCRT-associated protein ALIX 
[ALG-2 (apoptosis-linked gene 2) interacting protein X], which inhibits formation of 
intralumenal vesicles (10, 46). Knockdown of all candidates was nearly complete at protein 
level (Fig. S2A). To evaluate the effects of ESCRT inactivation on the EGF transcriptional 
response, mRNA abundance for each time point under each knockdown condition were 
normalized to the mock-treated control without EGF (Fig. 3B). This analysis showed that 
the overall EGF-dependent response was not affected by any knockdown condition at any 
time point (Fig. 3A-B). The overall profile of transcripts with EGF-induced increases in 
abundance remained similar to that of controls, and no kinetic delay was observed. 
Principal component analysis showed that triplicates as well as time points clustered 
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together, and that the major source of data variability originated from EGF stimulation and 
not from the knockdowns (Fig. S2B). 
 
To better reveal possible changes in gene expression resulting from the depletion of 
HRS or other ESCRTs, mRNA values for each each knockdown were normalized to the 
corresponding mock-treated controls at each time point. This representation minimizes the 
effects of EGF on transcription. Values were then ranked according to the magnitude of the 
effect and compared with the other knockdown conditions (Fig. S4A-D). This analysis 
revealed that, although only a small number of transcripts were decreased, HRS knockdown 
increased the abundance of 25 transcripts by >200%, several of which have been associated 
with cancer, cell proliferation, and NF-κB (nuclear factor κB) and cytokine signaling 
(Table S3). Knockdown of other ESCRTs resulted in less pronounced and fewer changes 
(Fig. S4A-D). Thus, in contrast to phosphorylation of EGFR, MEK and ERK (Fig. 2D and 
Fig. S1), gene expression seemed to not be uniformly affected by depletion of different 
ESCRT subunits although all act along the same pathway. 
 
HRS and to some extent TSG101 depletion specifically affects NF-κB and cytokine 
signaling 
To further substantiate our findings, we used an independent strategy to assess the quality 
of the microarray data. Transcripts were analyzed with NanoString, an approach that 
provides high sensitivity and broad dynamic range without the potential bias introduced by 
amplification (47, 48). We selected 100 genes that encode proteins involved in EGFR 
trafficking and signaling (Fig. 3C and Table S4A) as well as control genes for 
normalization and knockdown verification (Fig. S2A). Corresponding transcripts were 
measured in the same samples, which were used in the array-based analysis. In addition, we 
also included the knockdown of the Bro1 domain-containing putative phosphatase HD-PTP 
(His-domain-containing protein tyrosine phosphatase), which promotes EGFR degradation 
(49), in contrast to ALIX (49-52). Similar to microarray experiments, principle component 
analysis showed that triplicates and time points clustered together, with the major source of 
variability caused by EGF stimulation and not by knockdowns (Fig. S2C). Transcription 
profiles obtained with NanoString were similar to those observed with microarrays (Fig. 
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S2D). Differences in absolute transcription values likely reflect the higher dynamic range 
and sensitivity of the NanoString technology. A clear time dependence of the EGF-induced 
transcriptional program was observed and the overall organization of this response was not 
changed under any knockdown condition (Fig. 3C), as in the microarray analysis. 
Similarly, normalization to mock-treated samples at each time point after EGF addition 
(Fig. 3D) revealed knockdown effects, and, as observed in the microarray analysis (Fig. 
S4A-D), HRS depletion had a stronger effect than other knockdown conditions (Fig. 3D). 
 
Beyond the observations that the general architecture of the response remained 
unaltered, interfering with ESCRT subunits clearly affected the expression of some specific 
genes. To investigate these changes in more detail, data were analyzed with the Ingenuity 
IPA software in an unbiased fashion to reveal possible pathways or networks common to 
ESCRT depletion. The most prominent network contained genes affected by depletion of 
HRS and TSG101, particularly at late time points after EGF stimulation. The computed 
network was enriched in genes implicated in NF-κB and cytokine signaling, consistent with 
the independent analysis of transcripts showing increased abundance after HRS knockdown 
(Table S3C-D). These include NFKB1 and 2, NFKBIA (or IκBα), TNFAIP3, BIRC3, IL6, 
PTGS2 (or cyclooxygenase 2), and CCL2 (Fig. S4E-F). The fact that the same pathway is 
affected by HRS or TSG101 depletion ruled out indirect or off-target effects. Manual 
analysis uncovered more genes of the same network that were transcriptionally affected 
(IL8, CXCL2, ZFAND5, and IRF1). Moreover, some genes regulating NF-κB signaling 
were only affected by HRS depletion (NFKBIE [or IκBε], REL and RELB, as well as 
RHEBL1). In general, the impact of HRS knockdown on the expression of those genes was 
more pronounced than that of TSG101 knockdown. Hence, although depletion of the 
ESCRT subunits has no overall influence on EGFR signaling, HRS and to some extent 
TSG101 depletion may specifically affect NF-κB and cytokine signaling in HeLa cells. 
 
The global architecture of the response to high, low or pulsed EGF doses is similar  
We wondered whether the apparent discrepancy in the knockdown effects on 
phosphorylation of EGFR and MAPK compared to downstream transcriptional activation 
might reflect differences in EGF stimulation. The transcriptomic analysis was carried out 
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without cycloheximide because the EGF response depends on protein synthesis, but the 
analysis of EGFR degradation had to be carried out with cycloheximide to prevent 
synthesis of new EGFR. Without cycloheximide, EGFR was re-synthesized at late time 
points (Fig. 4A) leading to possible reactivation of the cascade in the presence of EGF. To 
address this issue, cells were briefly stimulated with EGF and then further incubated 
without ligand. However, extent and kinetics of phosphorylation of EGFR and MAPK, with 
or without cycloheximide, were comparable to those observed after continuous stimulation 
(Fig. 4A-B and Fig. S5). Moreover, independent of the EGF stimulation condition, 
cycloheximide had a major impact on the activity status of cascade components, as 
anticipated (Text S1), and should thus be omitted when studying signaling responses.  
 
Using NanoString, we then investigated the transcriptional response to the short pulse, 
or to continuous EGF stimulation using a low EGF dose, because EGFR trafficking may be 
differentially affected by the EGF dose (22, 26). To ensure an adequate comparison, fifty 
genes from previous experiments (Fig. 3C-D) were measured, and 40 new genes were 
selected from our microarray data (Fig. 3A-B) and 10 genes were used for normalization 
(and knockdown verification) (Text S2, and Fig. S6). To analyze the transcriptional 
response under these conditions, data were normalized to values from unstimulated cells 
and grouped according to the peak of induction (as in Fig. 3A-C). The global architecture 
of the response observed with high, low and pulsed EGF doses was similar (Fig. 4C). To 
reveal condition-specific effects, data were normalized to values obtained with the high 
EGF dose at each time point (Fig. 4D). Although the duration of transcription was reduced 
with the low EGF dose (Fig. 4D, 360 min), some transcripts were increased in abundance at 
early time points particularly after the pulse (Fig. 4D, 30 min), including transcripts 
encoding components of the immediate early and delayed early EGF response (for 
example, EGR3, FOSB, NR4A family members, IL8 and IL6; see Fig. 3B for comparison). 
This temporal increase in the transcriptional response is likely due to delayed 
internalization of EGFR molecules or more efficient recycling. Moreover, the observations 
that the architecture of the response is essentially identical when triggered by a brief EGF 
pulse or by the continuous presence of the ligand, not only at the protein (Fig. 4A-B) but 
also at the transcriptional level (Fig. 4C-D), argues that the complete transcriptional 
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program is elicited within a short time after ligand binding. Presumably, the induction of 
immediate early genes such as activating transcription factors (Fig. S3A) and their 
regulators (Fig. S3B) is sufficient to determine subsequent events of the response and thus 
its architecture. 
 
Interfering with EGFR endocytosis and ubiquitination upregulates the EGF-
dependent transcriptional program 
Endosomal sorting of EGFR molecules through ESCRT proteins did not appear to regulate 
the global architecture of the EGF transcriptional response nor its amplitude, although it 
may control NF-κB and cytokine signaling. We thus decided to investigate whether the 
EGF response was regulated by receptor sorting upstream of ESCRTs in more detail. To 
this end, we depleted cells of both clathrin heavy chain and dynamin 2 (Fig. S6A), both of 
which mediate EGFR internalization (17, 53). Cells were also depleted of both CBL and 
CBLB ubiquitin ligases (Fig. S6B). Although the relative contribution of their different 
targets, hence direct compared to indirect roles, is unclear, these proteins are involved in 
EGFR internalization (24, 54, 55) and cooperate in stimulus-dependent EGFR 
ubiquitination (56). The role of EGFR ubiquitination in internalization has been debated; 
however, the addition of ubiquitin to EGFR is essential for lysosomal targeting and 
degradation (7, 8). 
 
As expected, EGFR degradation was reduced after EGF addition in cells prepared after 
double knockdown of clathrin heavy chain and dynamin 2 (Fig. 5A) or CBL and CBLB 
(Fig. 5B) compared to mock-treated controls. Similarly, each double knockdown also 
increased the amounts of phosphorylated EGFR, MEK1/2 and ERK1/2, and rapid 
dephosphorylation required protein synthesis (Fig. 5A-B), as expected (Fig. 4). The 
increased abundance and phosphorylation of EGFR abundance and the increased 
phosphorylation of downstream kinases (Fig. 5A-B) were comparable with each double 
knockdown, although effects were somewhat stronger in CBL- and CBLB-depleted cells 
(Fig. S7 and Table S1). Moreover, EGFR abundance and phosphorylation state in cells with 
these double knockdowns were similar in extent to those detected in cells depleted of 
ESCRTs (Fig. 2D and Fig. S1). Despite this similarity, luciferase activity in our reporter 
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assay was increased to ≈150% after depletion of clathrin heavy chain and dynamin 2 alone 
or together, compared to mock treatment (Fig. 5C), consistent with increased 
phosphorylation of MAPK (Fig. 5A) but in contrast to the situation observed after 
knockdown of ESCRT proteins (Fig. 2). Knockdown of CBL and CBLB also increased 
ELK1-driven luciferase expression to the same extent as knockdown of clathrin heavy 
chain and dynamin 2 (Fig. 5D). By contrast, double knockdown of ALIX and TSG101, to 
interfere simultaneously with intralumenal vesicle formation mediated by ESCRTs and by 
the ALIX-binding unconventional late endosomal lipid LBPA (lysobisphosphatidic acid) 
(57) did not cause any effect (Fig. 5D), despite efficient protein depletion (Fig. S6C). 
Interfering with ubiquitination had a stronger impact than depletion of ubiquitin-binding 
ESCRT subunits, perhaps because ubiquitin mediates interaction with multiple partners. 
We conclude that, although the effect of interfering with clathrin and dynamin 2 or with 
CBLs is the same at the protein level as interfering with ESCRT functions (compare Fig. 
2D with Fig. 5A-B), the transcriptional response is different (compare Fig. 2B with Fig. 
5C-D). 
 
When stimulated with EGF, the receptor was efficiently internalized within 10 min into 
early endosomes containing EEA1 in mock-treated controls (Fig. 6A). Unbiased automated 
quantification with CellProfiler software showed that the bulk of endocytosed EGFR 
colocalized with EEA1 (Fig. S8A). Depletion of clathrin heavy chain or dynamin 2 
inhibited the appearance of EGFR into EEA1-containing endosomes (Fig. 6B) to ≈30% of 
the control (Fig. S8A). However, the majority of endocytosed EGFR still colocalized with 
EEA1, as expected. Similarly, double knockdown of CBL and CBLB also reduced EGFR 
content in endosomes, although to a somewhat lesser extent, whereas depletion of HRS and 
TSG101 only had a small effect (Fig. 6C-E and quantification in Fig. S8A). Quantification 
of total EGFR fluorescence intensity per cell confirmed that these differences did not result 
from differences in EGFR abundance (Fig. S8B). Because EGFR internalization into 
EEA1-containing endosomes was reduced by double knockdown of clathrin heavy chain 
and dynamin 2 or CBL and CBLB (Fig. 6B-C and Fig. S8A), we quantified the receptor 
present at the plasma membrane in the absence of permeabilization. EGFR rapidly 
disappeared from the surface of mock-treated cells, with ≈20% remaining after 10 min (Fig. 
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S8C-D). Consistent with the inhibition of EGFR appearance in early endosomes, double 
knockdown of clathrin heavy chain and dynamin 2 significantly increased the abundance of 
EGFR at the plasma membrane, as did double knockdown of CBL and CBLB, albeit to a 
lesser extent, whereas knockdown of HRS or TSG101 did not have this effect (Fig. S8C-
D). Eventually, internalized EGFR was transported to LAMP1-containing compartments 
within 60 min under all conditions tested, when analyzed in the presence of leupeptin to 
inhibit lysosomal degradation (Fig. S8E and S9), as expected (37). 
 
These observations are consistent with the notion that receptor internalization is 
impaired after knockdown of clathrin heavy chain and dynamin 2 (17, 53). Our data also 
support the notion that in CBL- and CBLB-depleted cells, EGFR endocytosis is reduced 
(54). In addition, defective ubiquitination increases cell surface receptors by facilitating 
EGFR recycling (58, 59) — as may be the case to some, albeit lower, extent after HRS and 
TSG101 depletion (44). 
 
To further investigate the EGF response after depletion of clathrin heavy chain and 
dynamin 2 or CBL and CBLB, we carried out a transcriptional analysis with NanoString 
(Fig. 7) of exactly the same genes as in the study of different EGF stimulation conditions 
(Fig. 4). In this analysis, we included cells prepared after double knockdown of ALIX and 
TSG101, which did not affect ELK1-driven luciferase in contrast to double knockdown of 
CBL and CBLB or clathrin heavy chain and dynamin 2 (Fig. 5C-D). We also included as 
positive controls cells that overexpressed EGFR approximately 2-fold over the endogenous 
amount (Fig. 1C and Fig. S6D), and cells treated with PMA which activates the 
ERK/MAPK cascade (Fig. 1D) through PKC rather than through EGFR (33). 
 
When data were normalized to the corresponding time 0 values to illustrate the 
transcriptional response to EGF (Fig. 7A), it revealed that, like after ESCRT depletion (Fig. 
3C), the overall architecture of transcription was comparable to the controls under all 
conditions tested, except PMA. Treatment with PMA not only increased transcription at 
120 and 360 min but also shifted or prolonged the response in time (Fig. 7A and Text S2), 
because it increased luciferase activity in the signaling assay (Fig. 1D). This demonstrates 
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both that global changes in the architecture of the response can occur if triggered with 
appropriate stimuli, and that these changes can be detected with NanoString. To better 
reveal the possible effects of the treatments on transcription, data were normalized to the 
corresponding control values at each time point. This analysis confirmed that PMA 
generally increased and prolonged transcription (Fig. 7B), whereas double knockdown of 
ALIX and TSG101 affected transcription only at 30 min (Fig. 7B). In addition, this analysis 
revealed that double knockdown of clathrin heavy chain and dynamin 2 further increased 
the expression of many EGF-dependent transcripts at all time points (Fig. 7B). The effects 
of CBL and CBLB depletion were similar to those caused by double knockdown of clathrin 
heavy chain and dynamin 2, as were the effects of EGFR overexpression (Fig. 7B). Under 
each one of these three conditions, the expression of same EGF-dependent transcripts were 
increased, without global changes in the organization of the response (Fig. 7A). These three 
conditions clustered together in the principal component analysis (Text S2 and Fig. S6E-F) 
as well as upon unsupervised hierarchical clustering (Fig. S10). The ability of EGFR 
overexpression to mimic the changes in the EGF response caused by double knockdown of 
CBLand CBLB or clathrin heavy chain and dynamin 2 rules out the possibility that these 
changes are indirect or off-target. 
 
Like many cultured cell lines, HeLa cells are immortalized by transformation. To 
determine whether our observations were more generally applicable, we analyzed the EGF 
transcriptional response in the immortalized but non-transformed epithelial cell line 
MCF10A, which is derived from human fibrocystic mammary tissue. To allow appropriate 
comparison between cell lines, transcripts were measured in samples prepared after 
knockdown of the ESCRT subunits HRS and TSG101 as well as after depletion of VPS4A. 
Double knockdown of clathrin heavy chain and dynamin 2, to inhibit internalization, as 
well as double knockdown of CBL and CBLB, to interfere with ubiquitination, were also 
included, as were samples from cells treated with PMA as a positive control. We selected a 
group of 56 genes (Fig. S11A), which include targets of the EGF response that have been 
identified by others (43) and by us (Fig. 3), as well as control genes for normalization and 
knockdown verification (Fig. S11B). The transcripts were analyzed using the NanoString 
technology. Similar to HeLa cells, principal component analysis showed that biological 
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triplicates clustered together (Text S3 and Fig. S11C), demonstrating excellent 
reproducibility, and that the effects of both double knockdowns (clathrin heavy chain and 
dynamin 2 or CBL and CBLB) and PMA stimulation (blue and orange circle in Fig. S11D, 
respectively) clustered away from other conditions. The magnitude of the overall response 
in MCF10A cells appeared somewhat diminished when compared to HeLa cells, 
presumably reflecting the relative abundance of some key factors, and thus effects of 
ESCRT knockdown were less pronounced than in HeLa cells. However, a clear time 
dependence of the EGF-induced transcriptional program was observed, whose overall 
organization was not changed under any knockdown condition. Knockdown effects were 
revealed after normalization to mock-treated samples at each time point of EGF addition. 
Unsupervised hierarchical clustering revealed the similarity of the effect of double 
knockdown of clathrin heavy chain and dynamin 2 or CBL and CBLB (blue branches in 
Fig. S11A), whereas PMA-stimulated samples at 120 and 360 min constitute a separate 
branch (orange) due to a more general increase and shift of gene expression. This analysis 
confirmed that interfering with internalization and ubiquitination, but not with ESCRT 
functions, stimulated the EGF transcriptional response without affecting its general 
architecture, essentially duplicating our findings in HeLa cells.  
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DISCUSSION  
 
In Drosophila, hrs mutant larvae show expanded domains in the expression of EGFR 
signaling targets (34), and ESCRT mutants exhibit reduced degradation of the Notch 
receptor and ectopic Notch signaling (60-62), consistent with the notion that some ESCRTs 
act as tumor suppressors. However, it is not clear whether ESCRTs play this role in 
mammalian cells. TSG101 in particular was originally proposed to play a role in gene 
transcription as a cofactor or transcription factor (63), but its role in oncogenesis and 
transcriptional regulation, whether direct or indirect, is not clear (64), perhaps involving 
different mechanisms (65). Similarly, the role of HRS as a tumor suppressor has been 
questioned (66). 
 
However, interfering with ESCRT functions clearly prolongs the half-life of EGFR and 
other receptors by reducing lysosome targeting. We found that this increase in EGFR 
abundance and phosphorylationdid not affect the EGF transcriptional response over the 
(short) time course corresponding to the full deployment of the EGF-dependent 
transcriptional program. By contrast, in ESCRT mutant animals over the long time course 
of embryogenesis, both distribution and amounts of EGFR and other receptors are 
eventually changed, thus altering transcription. We found that the acute EGF-dependent 
wave of transcription can be enhanced by increasing receptors at the cell surface and 
perhaps in recycling endosomes, by EGFR overexpression or by blocking internalization or 
ubiquitination. Overexpression increases the number of EGFR molecules, but also their 
residence time at the cell surface in the presence of EGF due to saturation of endocytic 
routes (67-69), enhancing the mitogenic potency of EGF (70). Indeed, increased abundance 
of EGFR or ERBB2 (or both), which results in internalization- and ubiquitination-deficient 
heterodimers (16, 69), can be found in many types of cancer (71). 
 
Our data indicate that the complete and well-structured transcriptional program elicited 
by EGF is set in motion within a short time period after ligand binding to the receptor, by 
inducing the expression of immediate early genes that determine the subsequent 
architecture of the response. Our data also show that the transcriptional response is 
triggered primarily by a pool of receptor molecules present at the cell surface or on 
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recycling membranes. The replication of these findings in non-cancer derived normal 
diploid cells suggests that our conclusions are generally applicable. Early ESCRTs such as 
HRS and TSG101 have been proposed to function at a stage of endosome maturation from 
which recycling is possible, whereas ESCRT-II and -III function at a maturation stage after 
recycling (72). We speculate that ubiquitination defines the molecular checkpoint, beyond 
which receptor molecules are committed and no longer competent to influence the 
transcriptional response. In addition, our results indicate that interfering with early ESCRT 
functions, in particular HRS, affects NF-κB and cytokine signaling. However, our data also 
show that, once set in motion, the EGF transcriptional program is robust and tolerates 
changes in the timing of the activation states of the kinases, presumably due to the tight 
balance of feedback mechanisms (45). 
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MATERIALS AND METHODS 
 
Reagents, antibodies, siRNAs and constructs 
For cell culture, Dulbecco's Modified Eagle Medium (DMEM) - high glucose from Sigma-
Aldrich (St. Louis, MO), or DMEM/F-12 - GlutaMAX from Gibco-BRL (Gaithersburg, 
MD) was used. Fetal calf serum (FCS) was from Brunschwig (Basel, Switzerland), and 
horse serum from BioConcept (Allschwil, Switzerland). L-glutamine, penicillin and 
streptomycin, phenol red-free DMEM (high glucose, 25 mM HEPES-buffered, without 
sodium pyruvate) and Opti-MEM Reduced Serum Medium, were all from Gibco-BRL. 
Human EGF (used at 1.5 or 100 ng/ml for stimulation), insulin (5 µg/ml final 
concentration), dexamethasone (1 µM final), AG1478 (or “tyrphostin”, 150 nM final), 
PMA (phorbol 12-myristate 13-acetate, 10 ng/ml final), and cycloheximide (10 µg/ml final) 
were from Sigma. U0126 (10 µM final) was from Cell Signaling Technology (Danvers, 
MA), and luciferin (0.1 mM final) from Promega (Madison, WI). Transfection of cells with 
siRNAs was performed with Lipofectamine RNAiMAX (Invitrogen, San Diego, CA), and 
plasmid transfection was done with FuGENE HD Transfection Reagent (Roche 
Diagnostics, Basel, Switzerland). Mouse monoclonal antibodies were against EGFR (BD 
Biosciences, San Diego, CA), phospho-EGFR Tyr1173 (Upstate, Lake Placid, NY), 
MEK1/2 and phospho-ERK1/2 (Cell Signaling Technology), RAB5 (Reinhard Jahn, 
Goettingen, Germany), TSG101 (GeneTex, San Antonio, TX), and GFP (Roche). 
Polyclonal antibodies were raised in sheep against EGFR (BD Biosciences) and in rabbits 
against EEA1 (Alexis Biochemicals, Lausen, Switzerland), LAMP1 (Thermo Fisher 
Scientific, Lafayette, CO), phospho-MEK1/2 and ERK1/2, (Cell Signaling Technology), 
SNX3 (Wanjin Hong, Singapore), HRS (Harald Stenmark, Oslo, Norway), ALIX (Rémy 
Sadoul, Grenoble, France), DNM2 and CHC (Abcam, Cambridge, UK), as well as VPS4, 
CBL and CBLB (Santa Cruz Biotechnology, Santa Cruz, CA). Horseradish peroxidase-
conjugated secondary antibodies were from Invitrogen or GE Healthcare (Chalfont St. 
Giles, UK), and fluorophore-coupled secondary antibodies from Jackson ImmunoResearch 
(West Grove, PA). Protein depletion was performed with ON-TARGETplus SMART pool 
siRNAs from Dharmacon (Thermo Fisher Scientific) (Table S5). Plasmids used were 
pEGFP-RAB5(Q79L) (Marino Zerial, Dresden, Germany), pEGFP-EGFR (Alexander 
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Sorkin, Pittsburgh, PA) and the parental vector pEGFP-N1 (Clonetech, Mountain View, 
CA). 
 
Cell culture, transfection, EGF stimulation, harvest of cells, and Western blotting 
Maintenance of HeLa luciferase reporter for ELK1 cells (HLR-ELK1; Stratagene, La Jolla, 
CA) was according to company´s instructions. MCF10A cells (ATTC, Manassas, VA) were 
grown in DMEM/F-12 medium supplemented with horse serum (5% v/v), antibiotics, 5 
µg/ml insulin, 1 µM dexamethasone, and 10 ng/ml EGF. Transfection of siRNAs was 
performed using Lipofectamine RNAiMAX according to manufacturer´s instructions, and 
cells were grown for two days to a confluency of about 80%. Plasmid transfection with 
FuGENE HD Transfection Reagent was according to manufacturer´s instructions. 
Before EGF stimulation, cells were starved for 16 hours in serum-free medium, and then (3 
days after transfection) continuously stimulated for the indicated times with 100 ng/ml 
EGF. Other stimulation conditions were: (i) 5 min EGF pulse followed by washes and a 
chase with serum-free medium, (ii) continuous stimulation with 1.5 ng/ml (“low”) EGF, or 
(iii) PMA treatment at a final concentration of 10 ng/ml. For EGFR degradation time 
courses, cycloheximide was added to a final concentration of 10 µg/ml. The cells were 
washed twice with PBS at 4°C, and harvested in cell lysis buffer (Cell Signaling 
Technology). Protein quantification was with the protein assay reagent from Bio-Rad 
Laboratories (Hercules, CA), as described (73). Samples were then processed for standard 
SDS-PAGE (74, 75) and Western blotting analysis (76, 77). Where indicated, 
quantification of Western blots was done with ImageJ software v1.45d. Further calculations 
and statistical analyses, two-way ANOVA and Bonferroni post hoc tests, were done with 
Microsoft Excel 2010 and GraphPad Prism v5.04 software. For RNA extraction, cells were 
scraped in 350 µl RLT lysis buffer (Qiagen, Valencia, CA), snap-frozen and stored at -
80°C until RNA purification. 
 
Microscopy 
Cells were transfected as above, and the next day split into cover slip-containing dishes. 
Before stimulation (100 ng/ml continuous EGF, where indicated in the presence of 150 
ng/ml leupeptin), cells were starved for 16 hours. Sample preparation for 
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immunofluorescence was as described (78, 79). Pictures were captured using a Leica TCS 
SP2 AOBS confocal microscope, equipped with a Leica 100x Plan-Apochromat oil 
immersion objective, or a Zeiss LSM 700 confocal microscope with a Zeiss 63x Plan-
Apochromat oil immersion objective; total EGFR fluorescence was done with a Zeiss 20x 
Plan-Apochromat objective. Colocalization analysis was performed using the CellProfiler 
software v2.0, and quantification of total EGFR fluorescence with ImageJ. Further 
calculations and Student´s t-tests were done with Microsoft Excel 2010. 
 
Live-cell signaling assay and quantitative real-time RT-PCR 
To measure EGF-induced luciferase activity, HLR-ELK1 cells were split one day after 
transfection into 3.5 cm dishes in duplicates. The next day, cells were starved for 8 hours in 
serum-free DMEM, and then washed with phenol red-free DMEM supplemented with 
antibiotics. Stimulation was in the same medium in the continuous presence of 0.1 mM 
luciferin and 100 ng/ml EGF, at 37°C in a light-tight incubator. Bioluminescence was 
monitored continuously for up to 16 hours using Hamamatsu photomultiplier tube detector 
assemblies (80, 81). Photon counts were integrated over 10 min intervals. Data were 
analyzed with the LumiCycle v1.4 software (Actimetrics, Wilmette, IL) and Microsoft 
Excel 2010. 
For quantitative real-time RT-PCR (qRT-PCR), purification of total RNA using the 
RNeasy Mini Kit from Qiagen was done according to manufacturer´s instructions. RNA 
concentrations were measured with the NanoDrop ND-1000 UV/Vis Spectrophotometer 
(NanoDrop Technologies, Wilmington, DE). 1 µg RNA was used for primer annealing 
(with QuantiTect Primer Assays for human EGR1, FOS, and ACTB from Qiagen). Reverse 
transcription (with SuperScript enzyme, Invitrogen), and PCR with QuantiTect SYBR 
Green PCR Kits (Qiagen), were done according to manufacturer´s instructions. Monitoring 
of cDNA amplification was with the iCycler from Bio-Rad, and data were analyzed with 
the iCycler IQ v3.1 software and Microsoft Excel 2010. 
 
Sample preparation for microarray analysis 
HLR-ELK1 cells were grown, transfected, starved for 16 hours, stimulated, and harvested 
in RLT buffer as described above. For each transfection, four time points of EGF 
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stimulation (0, 30, 120, and 360 min) were assayed in independent biological triplicates, 
and one dish was prepared simultaneously to determine protein depletion by Western 
blotting. The same lots and batches of media, FCS, transfection reagents, siRNAs, and EGF 
or PMA were used throughout the procedure, to exclude any possible batch effects. 
Purification of total RNA was as above. Concentration, purity and integrity of the RNA 
were measured with the Picodrop Microliter UV/Vis Spectrophotometer (Picodrop, Saffron 
Walden, UK), and the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), 
together with the RNA 6000 Series II Nano Kit (Agilent) according to manufacturer´s 
instructions. 
We used the Human Gene 1.0 ST Array Reagent Kit (Affymetrix, High Wycombe, 
Buckinghamshire, UK) for microarray target amplification, and for labeling we used the 
GeneChip Whole Transcript Sense Target Labeling Assay (Affymetrix). Target preparation 
as well as hybridization, washing and scanning was performed according to manufacturer´s 
instructions, as described (82). In general, all samples were processed simultaneously, 
except for cleanup steps and the hybridization till scanning procedure. There, one replicate 
of each condition was processed at the same time, in order to minimize possible batch 
effects due to sample handling. Sample preparation was according to the 100 ng Total RNA 
Labeling Protocol. Differing from the protocol, 200 ng of total RNA were used as starting 
material for the first-strand cDNA synthesis. 
 
mRNA measurements using the NanoString technology 
The same samples analyzed by microarrays were also measured with the NanoString 
nCounter gene expression system (47, 48) from NanoString Technologies (Seattle, WA). A 
second, independent measurement was performed in HeLa (HLR-ELK1) cells, and a third 
experiment was done with MCF10A cells. All target sequences for the three NanoString 
analyses are summarized in Table S4A-C. Cell growth, transfection, starvation, stimulation, 
and harvest were identical to the microarray experiment, except that DMEM/F-12 medium 
was used for MCF10A cells, and biological triplicates were prepared for each condition. 
Assay set-up (combining reporter probes, mRNA, and capture probes), hybridization at 
65°C for at least 12 hours, post-hybridization processing using the nCounter Prep Station, 
and scanning with the nCounter Digital Analyzer (NanoString) were done according to 
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manufacturer´s instructions, as described (83), except that 300 ng of mRNA were used as 
starting material. 
 
Software used for normalization and analysis of transcriptome data 
The raw microarray data files were generated using the Affymetrix GeneChip Operating 
Software. Normalization (according to the RMA procedure) was done with Partek 
Genomics Suite v6.5 (St. Louis, MO), and a batch removal step was performed to eliminate 
possible effects of the scan date. We used R.2.6 together with the affy, limma and 
geneplotter packages from the bioconductor platform and MS Excel 2010 in order to: (i) 
further normalize (to the mock-treated sample at time 0 to illustrate the EGF response, or to 
the corresponding mock values at each time point to visualize effects of the various 
conditions); (ii) define a cut-off (1.8-fold difference to mock 0 min EGF); (iii) group 
(according to the peak of expression); and (iv) rank genes (according to the strength of 
induction). Values from NanoString measurements were normalized to multiple 
housekeeping genes (84), using an Excel-based macro (83). Further normalization, 
grouping and ranking was as above. 
Heat maps were created with Partek, and additionally processed for visualization with 
Adobe Illustrator CS4 v14.0 (Adobe, San Jose, CA). GeneSpring GX v7.3 (Agilent) and 
MS Excel was used to create lists of affected genes in knockdown conditions, and pathway 
analysis was performed for those genes with Ingenuity pathway analysis IPA v7.6 software 
(Ingenuity Systems, Redwood City, CA). Lists of EGF-induced genes and of genes affected 
by knockdowns in the microarray analysis can be found in Table S2 and S3A-D, 
respectively (85). 
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SUPPLEMENTARY MATERIALS 
 
Text S1. Analysis of the different conditions of stimulation. 
Text S2.  Quality control for the second NanoString analysis.  
Text S3. Quality control for the third NanoString analysis. 
Fig. S1. Quantification of EGFR, as well as phosphorylated EGFR and downstream 
kinases, after depletion of ESCRT proteins. 
Fig. S2. Quality controls for microarrays and the first NanoString measurement. 
Fig. S3. Known EGF-induced feedback regulators from microarray analysis. 
Fig. S4. Magnitude and comparison of ESCRT knockdown effects in the microarrays, and 
network analysis of HRS and TSG101 knockdown effects. 
Fig. S5. Quantification of EGFR, as well as phosphorylated EGFR and downstream 
kinases, under different conditions of stimulation with EGF. 
Fig. S6. Quality controls for the second NanoString experiment and comparison to the first 
data set. 
Fig. S7. Quantification of abundance and phosphorylation of EGFR and phosphorylation of 
downstream kinases after various double knockdowns. 
Fig. S8. Analysis of EGFR distribution. 
Fig. S9. EGFR localization after 60 min of EGF stimulation. 
Fig. S10. Hierarchical clustering of the transcriptional response and of effects in the second 
NanoString experiment. 
Fig. S11. Hierarchical clustering of effects in the third NanoString experiment and quality 
controls. 
Table S1. Two-way ANOVA analysis of quantification of EGFR and phosphorylated 
EGFR, MEK1/2, or ERK1/2. 
Table S2. Microarray analysis of EGF response genes. 
Table S3. Microarray analysis of knockdown effects. 
Table S4. Target sequences of the NanoString code sets. 
Table S5. siRNA target sequences. 
Table S6. Microarray analysis of all EGF response genes. 
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FIGURE LEGENDS 
 
Fig. 1. Live-cell signaling assay. (A) Luciferase activity was measured while incubating 
HLR-ELK1 cells without (grey) or with 100 ng/ml EGF alone (black) or with AG1478 
(red). The raw data (in separate duplicates) are normalized to protein. (B) Luciferase 
activity in mock-treated (black) or EGFR-depleted (red) cells was normalized as time “0” 
to the mock peak value (n = 2 experiments, each in duplicates). (C-F) Luciferase activity 
was measured and normalized as in (B) in cells expressing GFP (black) or GFP-EGFR (red; 
n = 4 experiments) (C), cells treated with EGF (black) or PMA (red; n = 7 experiments) 
(D), mock-treated (black) or treated with siRNAs against MEK1 and MEK2 (red; n = 2 
experiments) (E), treated with EGF in the absence (black) or presence (red) of U0126 (n = 
2 experiments) (F). (G) Cells were treated with EGF or PMA with or without AG1478 and 
analyzed by Western blotting using antibodies against EGFR or the phosphorylated forms 
(P-) of the indicated proteins. (H-J) Cells treated with siRNAs against EGFR (H) or MEK1 
and MEK2 (J) or cells overexpressing GFP-EGFR (I) were analyzed by Western blotting. 
 
Fig. 2. Receptor sorting, signaling and phosphorylation after depletion of ESCRT proteins. 
(A) Cells treated (KD) or not (mock) with HRS siRNAs and expressing GFP-RAB5(Q79L) 
were incubated with EGF for 30 min and analyzed by indirect immunofluorescence with 
anti-EGFR antibody. In the right panel, EGFR in the endosome lumen is expressed as a 
percentage of the total in each endosome (≥ 30 endosome scans per condition; ****P < 
0.0001, Student´s t-test; n = 4 experiments). Scale bar, 10 µm. (B) Luciferase activity in 
mock-treated (black) or in cells treated with siRNAs against HRS (green) or TSG101 (blue) 
was measured and normalized as in Fig. 1B-F (TSG101, n = 10 experiments; HRS, n = 5 
experiments). (C) Cells mock-treated or treated with siRNAs against the indicated targets 
were incubated with EGF for 0 or 30 min and then analyzed by qRT-PCR for endogenous 
EGR1 and FOS mRNAs. Data represent ddCt values (number of PCR cycles between non-
induced and EGF-induced, normalized to actin) (P > 0.05, Student´s t-test; n = 3 
experiments performed in triplicates). (D) Cells mock-treated or treated with siRNAs 
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against the indicated targets were stimulated with EGF in the presence of cycloheximide for 
the indicated time (in hours), and analyzed by Western blotting as in Fig. 1G (quantification 
in Fig. S1 and statistical analysis in Table S1). 
 
Fig. 3. Architecture of the transcriptional EGF response after ESCRT depletion. (A-B) 
Cells mock-treated (m) or treated with siRNAs against HRS (H), TSG101 (T), VPS4A (V) 
or ALIX (A), were incubated with EGF for the indicated time. The heat map in (A) shows 
263 genes whose transcription was at least 1.8-fold above or below that in mock-treated 
samples at t = 0 min (no EGF). Data represent means of independent biological triplicates, 
and values for each gene are normalized to mock-treated controls at t = 0 min (white; fold 
change = 1; log2(1) = 0). Genes were further grouped according to their peak (or minimum) 
of expression in mock-treated cells and ranked according to decreasing fold change. (B) 
shows a magnified view of immediate early and top delayed early genes from (A). (C and 
D) 100 genes (Table S4A) from the same samples as in (A) and (B) were analyzed using 
NanoString, including HD-PTP (P) knockdown samples prepared in parallel. In (C), 
normalization, grouping and ranking was as in (A). In (D), values were normalized to the 
mock-treated controls at each time point. White lanes (fold change = 0) corresponding to 
mock-treated controls were omitted for clarity. All values are given as log2. 
 
Fig. 4. Effect of different EGF stimulation conditions on the transcriptional response. (A) 
Cells treated with 100 ng/ml EGF for the indicated time (in hours), with or without 
cycloheximide, were analyzed by Western blotting as in Fig. 2D. (B) As in (A), except that 
cells were treated with EGF for 5 min only followed by washes and a chase without EGF in 
serum-free medium. Quantification of the data in (A) and (B) is in Fig. S5 and statistical 
analysis in Table S1. (C and D) Cells were incubated for the indicated time in the absence 
of cycloheximide without or with 100 ng/ml EGF (high) as in (A), or with 1.5 ng/ml (low). 
Alternatively, cells were treated with 100 ng/ml EGF for 5 min in the absence of 
cycloheximide followed by a chase (p-ch) as in (B). The same group of 100 transcripts as in 
Fig. 7 was analyzed by NanoString (Table S4B; for quality controls see Text S2 and Fig. 
S6). In (C), data are normalized to values of unstimulated control samples, grouped and 
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ranked as in Fig. 3A-C. The t = 0 min control lane (white, fold change = 0) was omitted for 
clarity. In (D), the different stimulation conditions are compared by normalizing data to the 
corresponding values obtained after continuous stimulation with 100 ng/ml EGF. Values in 
(C) and (D) are in log2. 
 
Fig. 5. Interfering with internalization and ubiquitination. (A) Cells mock-treated or treated 
with siRNAs against both clathrin heavy chain and dynamin 2 (C + D2) were incubated 
with EGF for the indicated time (hours) in the presence or absence of cycloheximide. 
Samples were analyzed by Western blotting with antibodies that recognize EGFR, RAB5 or 
the phosphorylated forms of EGFR and downstream kinases. (B) Cells mock-treated or 
treated with siRNAs against both CBL and CBLB (B + C-CBL) were analyzed as in (A). 
Quantification of the data in (A) and (B) is in Fig. S7 and statistical analysis is in Table S1. 
(C) Luciferase activity was measured as in Fig. 1 and 2B in mock-treated (black) or in cells 
treated with siRNAs against clathrin heavy chain (dark red; n = 7 experiments), dynamin 2 
(red; n = 7 experiments), or both as in (A) (orange; n = 3 experiments). (D) Luciferase 
activity was measured in mock-treated (black) or in cells treated with siRNAs against CBL 
and CBLB as in (B) (green; n = 6 experiments) or against ALIX and TSG101 (blue; n = 3 
experiments). Data in (C) and (D) are normalized to the peak value of control cells. 
 
Fig. 6. EGFR distribution after 10 min of EGF stimulation. (A to E) Cells were mock-
treated (A) or treated with siRNAs against both clathrin heavy chain and dynamin 2 (B), 
CBL and CBLB (C), HRS (D), or TSG101 (E), and then incubated with EGF. Cells were 
analyzed by indirect immunofluorescence using antibodies against EGFR and EEA1. 
Quantification of the data is shown in Fig. S8A, quantification of total EGFR fluorescence 
is in Fig. S8B, and surface EGFR staining and quantification under the different 
knockdown conditions is in Fig. S8C-D. EGFR distribution after 60 min is shown in Fig. 
S9. Scale bar is 10 µm. 
  
Fig. 7. Comparative analysis of the transcriptional response. (A) Cells were mock-treated 
(Ctr) or treated with siRNAs against both clathrin heavy chain and dynamin 2 (C + D2), 
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against both CBLB and CBL (B + C), or against both ALIX and TSG101 (A + T) and then 
incubated with EGF for the indicated time. Cells overexpressing the EGFR were challenged 
with EGF, or cells were treated with PMA. A selected group of 100 transcripts 
(corresponding to Fig. 4) was analyzed by NanoString (see Table S4B and quality controls 
in Fig. S6). Data are normalized to values in unstimulated samples, grouped and ranked as 
in Fig. 3A-C and Fig. 4C. The t = 0 min control lanes (white, fold change = 0) were omitted 
for clarity. (B) The different treatments in (A) are compared to the values obtained with the 
EGF-treated controls. Data are normalized to each control at the corresponding time points. 
All values are in log2. 
020
40
60
80
100
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11
0
50
100
150
200
250
300
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11
0
50
100
150
200
250
300
350
400
450
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11
0
20
40
60
80
100
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11
0
20
40
60
80
100
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11
0
500
1000
1500
2000
2500
3000
3500
4000
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
A
N
or
m
al
iz
ed
 lu
ci
fe
ra
se
 a
ct
iv
ity
 (c
pm
)
Time of EGF stimulation (hours)
EGF
no EGF
EGF + AG1478
B
Time normalized to mock peak (hours)
mock siRNA
EGFR KD
C
Time normalized to GFP peak (hours)
GFP
GFP-EGFR
E
Time normalized to mock peak (hours)
mock siRNA
MEK1+2 dKD
F
Time normalized to EGF peak (hours)
EGF
EGF + U0126
no
 E
G
F
15
 m
in
 E
G
F
15
 m
in
 E
G
F
 &
 A
G
15
 m
in
 P
M
A
15
 m
in
 P
M
A
 &
 A
G
EGFR
P-EGFR
P-ERK1/2
P-MEK1/2
MEK1/2
G
m
oc
k 
si
R
N
A
M
E
K
1+
2 
K
D
MEK1+2
RAB5
HRS
J
EGFR
MEK1+2
SNX3
m
oc
k 
si
R
N
A
E
G
FR
 K
D
H
G
FP
G
FP
-E
G
FR
EGFR
GFP-EGFR
TSG101
GFP
I
D
EGF
PMA
Time normalized to EGF peak (hours)
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (%
 o
f m
oc
k 
pe
ak
)
Brankatschk – Fig. 1
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (%
 o
f m
oc
k 
pe
ak
)
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (%
 o
f m
oc
k 
pe
ak
)
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (%
 o
f m
oc
k 
pe
ak
)
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (%
 o
f m
oc
k 
pe
ak
)
020
40
60
80
100
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11
0
1
2
3
4
5
6
7
8
dd
C
t
m
oc
k
H
R
S
T
S
G
10
1
V
P
S
4A
m
oc
k
H
R
S
T
S
G
10
1
V
P
S
4A
EGR1  30 min FOS 30 min
B
mock siRNA
HRS KD
TSG101 KD
D
EGF :   0            1            3           5
m
oc
k 
si
R
N
A
H
R
S
 K
D
 
m
oc
k 
si
R
N
A
H
R
S
 K
D
 
m
oc
k 
si
R
N
A
H
R
S
 K
D
 
m
oc
k 
si
R
N
A
H
R
S
 K
D
EGFR
P-EGFR
P-ERK1/2
P-MEK1/2
RAB5
m
oc
k 
si
R
N
A
T
S
G
10
1 
K
D
 
m
oc
k 
si
R
N
A
T
S
G
10
1 
K
D
 
m
oc
k 
si
R
N
A
T
S
G
10
1 
K
D
 
m
oc
k 
si
R
N
A
T
S
G
10
1 
K
D
m
oc
k 
si
R
N
A
V
P
S
4A
 K
D
 
m
oc
k 
si
R
N
A
V
P
S
4A
 K
D
m
oc
k 
si
R
N
A
V
P
S
4A
 K
D
m
oc
k 
si
R
N
A
V
P
S
4A
 K
D
EGF : 0            1            3 5  EGF : 0            1            3           5  
C
Brankatschk – Fig. 2
A
****
0
10
20
30
40
50
60
70
mock HRS
Lu
m
in
al
 E
G
F
R
 [%
 o
f t
ot
al
]
m
oc
k 
si
R
N
A
H
R
S
 K
D
GFP-RAB5(Q79L)                  EGFR                             merge
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (%
 o
f m
oc
k 
pe
ak
)
Time normalized to mock peak (hours)
NanoString EGF response
(log2)0-2 8
360
120300
360
120300
360
120300
360
120300
360
120300
(log2)0-3 3
HRS        TSG101      VPS4A        ALIX         HD-PTP
NanoString KD effects
A B
EGF:   0 min           30 min          120 min         360 min
m  H  T  V   A   m  H   T  V   A   m  H   T   V  A   m  H   T  V   A
(log2)
0
-1.2
3.2
C D
EGF: 0 min             30 min            120 min          360 min
m  H  T  V  A   P  m H  T  V  A  P  m  H  T  V  A  P  m H   T  V  A  P
Brankatschk – Fig. 3
30 min      120 min      360 min
p-ch
low
high
p-ch
low
high
p-ch
low
high
30 min       120 min       360 min
p-ch
low
high
p-ch
low
high
p-ch
low
high
A
B
C
(log2)0-2 8
EGFR
P-EGFR
P-ERK1/2
P-MEK1/2
RAB5
0   0,5   1    2    3     4    5    6     8 0   0,5   1    2     3    4    5    6     8 
continuous EGF 
 cycloheximide                              − cycloheximide
EGFR
P-EGFR
P-ERK1/2
P-MEK1/2
RAB5
0    0,5   1    2     3     4    5    6     8 0  0,5   1     2     3    4    5     6     8
5 min EGF pulse – chase
 cycloheximide − cycloheximide
D
(log2)0-2 4
Brankatschk – Fig. 4
020
40
60
80
100
120
140
160
180
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11
0
20
40
60
80
100
120
140
160
180
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11
mock siRNA
CHC KD
DNM2 KD
CHC+DNM2 dKD
C
mock siRNA
B+C-CBL dKD
ALIX+TSG101 dKD
D
A
EGF : 0            1            3          5  
m
oc
k 
si
R
N
A
C
 +
 D
2 
dK
D
m
oc
k 
si
R
N
A
C
 +
 D
2 
dK
D
m
oc
k 
si
R
N
A
C
 +
 D
2 
dK
D
m
oc
k 
si
R
N
A
C
 +
 D
2 
dK
D
EGFR
P-EGFR
P-ERK1/2
P-MEK1/2
RAB5
0            1            3           5
m
oc
k 
si
R
N
A
C
 +
 D
2 
dK
D
m
oc
k 
si
R
N
A
C
 +
 D
2 
dK
D
m
oc
k 
si
R
N
A
C
 +
 D
2 
dK
D
m
oc
k 
si
R
N
A
C
 +
 D
2 
dK
D
 cycloheximide                − cycloheximide
B
m
oc
k 
si
R
N
A
B
 +
 C
-C
B
L 
dK
D
m
oc
k 
si
R
N
A
B
 +
 C
-C
B
L 
dK
D
m
oc
k 
si
R
N
A
B
 +
 C
-C
B
L 
dK
D
m
oc
k 
si
R
N
A
B
 +
 C
-C
B
L 
dK
D
EGFR
P-EGFR
P-ERK1/2
P-MEK1/2
RAB5
m
oc
k 
si
R
N
A
B
 +
 C
-C
B
L 
dK
D
m
oc
k 
si
R
N
A
B
 +
 C
-C
B
L 
dK
D
m
oc
k 
si
R
N
A
B
 +
 C
-C
B
L 
dK
D
m
oc
k 
si
R
N
A
B
 +
 C
-C
B
L 
dK
D
Brankatschk – Fig. 5
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (%
 o
f m
oc
k 
pe
ak
)
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (%
 o
f m
oc
k 
pe
ak
)
Time normalized to mock peak (hours) Time normalized to mock peak (hours)
EGF : 0            1            3          5  0            1            3           5
 cycloheximide − cycloheximide
m
oc
k 
si
R
N
A
C
H
C
+D
N
M
2 
dK
D
B
+C
-C
B
L 
dK
D
EGFR EEA1 merge
A
H
R
S
 K
D
B
C
D
T
S
G
10
1 
K
D
E
Brankatschk – Fig. 6
(log2)0-2 8 (log2)0-4 5
30 min                120 min               360 min                        PMA           A + T          B + C         C + D2  EGFR
360
120300
360
120300
360
120300
360
120300
360
120300
E
G
FR
C
 + D
2
B
 + C
A
 + T
P
M
A
C
tr
E
G
FR
C
 + D
2
B
 + C
A
 + T
P
M
A
C
tr
E
G
FR
C
 + D
2
B
 + C
A
 + T
P
M
A
C
tr
A B
Brankatschk – Fig. 7
